Retrospective cohort study shows relapse rates for rituximab and monoclonal antibodies in NMOSD, indicating novel therapies may offer better tolerability.
In this multicenter retrospective cohort study of 135 people with aquaporin‐4 IgG+ neuromyelitis optica spectrum disorder (NMOSD), some of whom were exposed to multiple therapies, we evaluated the effectiveness and tolerability of rituximab ( n = 111) and novel monoclonal antibodies (nMAbs): eculizumab ( n = 9), inebilizumab ( n = 23), and satralizumab ( n = 14). Over a median follow‐up of 3.92 years, 21/111 rituximab‐treated patients relapsed. In contrast, relapse occurred in only 1/23 inebilizumab‐treated patients (median follow‐up 1.27 years), with no relapses observed in those receiving eculizumab or satralizumab. Twelve‐month relapse‐free probabilities were 92% (rituximab), 94% (inebilizumab), and 100% (eculizumab and satralizumab). Among those with available MRI data, 10/73 rituximab and 1/14 inebilizumab developed new lesions. There were no serious adverse events. These findings support nMAbs as effective and well‐tolerated first‐line therapies for NMOSD.
No takes yet. Share an insight, caveat, or question.
Javed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: